Markets
Borrow
Earn
Invest
Private
Security
Newsroom
More
Log In
Sign Up
Markets
Market Overview
Indices and commodities.
Digital Credit
Bitcoin treasury preferreds.
AI Stocks
The artificial intelligence theme.
Bitcoin Treasuries
Companies holding bitcoin.
Economy
Sectors, global markets and rates.
Popular Portfolios
13F filings, smart money.
Borrow
Borrow
Borrow USDT or USDC against your BTC without giving it up.
ReFi
Switch your bitcoin-backed loan and pay less interest.
Earn
Carry Trade
Borrow, invest, keep the spread.
Stock Dividends
Dividends from tokenized equities.
Invest
Private
Security
Newsroom
More
Company
About Us
Our leadership team, mission, and investors.
Whitepaper
Vision, purpose, and architecture behind Roxom.
Legal
Terms, privacy, and disclosures.
Resources
Help Center
Guides, FAQs & support.
Rulebook
Trading logic, platform rules, and fundamentals.
API Docs
Connect, authenticate, and build with our API.
Status
Current platform health and incidents.
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
1 BTC
=
- USD
BTC
SATS
Loading market data...
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
CR
Cronos Group Inc. Common Share
CRON
Mkt Cap
$1.18B
Volume
842.09K
Next Earnings
November 5th
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
CR
CRON
CR
Cronos Group Inc. Common Share
CRON
News
·
Cronos Completes Acquisition of CanAdelaar, Europe’s Largest Adult-Use Cannabis Company
Mkt Cap
$1.18B
Volume
842.09K
Next Earnings
November 5th
Chart
Financials
Earnings
News
About
Insider
Filings
Cronos Completes Acquisition of CanAdelaar, Europe’s Largest Adult-Use Cannabis Company
Cronos Group has completed its acquisition of CanAdelaar B.V., the largest cannabis company in the Netherlands' adult-use cannabis pilot program (Wietexperiment), for a base purchase price of €57.5 million plus contingent cash earnouts. The acquisition establishes Cronos as the market leader in Europe's largest adult-use cannabis market and enables the company to execute its borderless product strategy in the Netherlands with CanAdelaar's proven operational track record and leading market share.
GlobeNewswire Inc. · Oct 15, 2026
CRON Stock Rises 17% in Three Months: Time to Buy the Dip or Cash Out?
Cronos Group shares rose 17% over three months following better-than-expected Q2 2026 results, with first-half revenues up 49% to $98.2 million driven by Canadian market share gains and international expansion. However, the company faces challenges including potentially unsustainable margin improvements, an Israeli anti-dumping investigation, and intensifying European competition from rivals like Village Farms and Tilray. Analysts maintain a cautious stance with unchanged earnings estimates.
Zacks Investment Research · Oct 9, 2026
2 Cannabis Stocks That Are Quietly Trouncing the Market in 2026
Trulieve Cannabis and Cronos Group have both gained approximately 27% in 2026, outpacing the S&P 500's 12% gain. Trulieve, now listed on the NYSE, generated $74 million in free cash flow in H1 2026 with a 60% gross margin. Cronos delivered 58% year-over-year revenue growth to $53 million in Q2 with expanding margins and $827 million in cash, while also returning capital to shareholders through share buybacks.
The Motley Fool · Sep 22, 2026
Why Trump Media Stock Just Sank 9.4%
Trump Media & Technology Group stock dropped 9.4% after unwinding its partnership with Crypto.com. The company scrapped plans for a digital-asset treasury company as the value of Cronos tokens collapsed from $0.20 to $0.047. Trump Media still holds crypto assets including Bitcoin and has taken substantial paper losses. With only $3.7 million in revenue against $530 million in losses over the past year, the company's $2.8 billion market cap appears disconnected from its fundamentals.
The Motley Fool · Aug 10, 2026
Canopy Growth Is Restating Two Years of Financials Before June 15 Earnings -- Here's What CGC Investors Need to Know Right Now
Canopy Growth announced it will restate financial results for two years due to a technical accounting error involving share-settled warrants that should have been classified as liabilities rather than equity. The company states the restatement won't impact revenue, operating income, cash flows, or key performance metrics. However, the stock remains a risky penny stock in a struggling marijuana sector facing intense competition and illicit market pressures. Most investors should avoid the stock until it achieves sustainable profitability and the restatement is complete.
The Motley Fool · May 23, 2026
From $500 to $1: Is Canopy Growth a Dead Stock Walking or the Ultimate Turnaround Play?
Canopy Growth has lost 99.6% of its value over five years due to persistent profitability challenges, inability to enter the U.S. market directly, heavy cash burn, and shareholder dilution. While the stock could experience a dead cat bounce, long-standing issues and political gridlock limiting federal marijuana legalization make further downside possible. The article recommends financially stronger cannabis alternatives like Green Thumb Industries and Cronos Group, or marijuana ETFs, as better investment choices.
The Motley Fool · Apr 22, 2026
The Major Long-Term Risk Facing Altria Stock in 2026
Altria faces a critical long-term challenge as its core cigarette business continues to decline with domestic shipments falling 10% in 2025. While the company has maintained profit growth through price increases, this strategy is unsustainable as smoking rates decline, particularly among young Americans. Although Altria's On! oral nicotine pouches show promise with 11% shipment growth, they face intense competition from Philip Morris's Zyn and lost market share in Q4. The company's diversification efforts have largely failed, and without successful next-generation products, Altria's stock faces eventual decline.
The Motley Fool · Mar 31, 2026
Recreational Cannabis Market Report 2026-2035: A $3.32 Billion Market by 2030 - AI-Enabled Product Innovation, Novel Cannabis Beverages and Experience-Based Offerings Reshape Premiumization
The recreational cannabis market is projected to grow from $2.24 billion in 2025 to $3.32 billion by 2030, with a CAGR of 7.8-8.2%. Growth is driven by increasing legalization, public acceptance, demand for high-THC products, and innovation in premium edibles, beverages, and vape formats. Key players are launching innovative products and pursuing strategic acquisitions to capitalize on expanding market opportunities.
GlobeNewswire Inc. · Feb 20, 2026
Format Innovation Reshapes a $438B Functional Market
The global functional food and beverage market is projected to reach $438 billion in 2026, with oral pouches and alternative caffeine delivery formats driving growth. Doseology Sciences launched caffeine-based energy pouches under its Feed That Brain brand, while Kraft Heinz introduced the HEINZ KegChup, Tilray Brands expanded spirits distribution in Illinois, Cronos Group launched Lord Jones cannabis in Israel, and USANA Health Sciences reported strong 2025 sales with positive 2026 guidance.
Benzinga · Feb 13, 2026
Cronos Group Launches Premium Lord Jones® Brand in Israel, Advancing Borderless Product Strategy
Cronos Group Inc. announced the launch of its Lord Jones premium cannabis brand in Israel, marking a significant expansion of its borderless product strategy. The initial launch includes five premium indoor-grown flower strains available in Israeli pharmacies, with plans for future special edition and limited-run products. The move reflects Cronos' commitment to international growth and building globally recognized cannabis brands.
GlobeNewswire Inc. · Feb 2, 2026
Holdings
Open Orders (0)
Positions (0)
Order History
Dividends
Transfers
Log In
to start trading
CR
CRON
Cronos Group Inc. Common Share
Buy
Sell
Market
Limit
Soon
CRON
25%
50%
75%
Max
Pay with
—
Start Trading
Available Balance
0.00
Your Position
You don't own any CRON yet.
Related Tickers
TL
TLRY
—
SN
SNDL
—
CG
CGC
—
OG
OGI
—
AC
ACB
—
Earnings